Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Scrip

Mens Health Drug Developments in Prostate Cancer

06 Nov 2018

November is Men’s Health Awareness Month, and Informa Pharma Intelligence is providing essential insights into drug developments for prostate cancer. Download now for free the "Men's Health: Drug Developments in Prostate Cancer Article Pack", brought to you by Scrip and Pink Sheet.

Topic Drug development landscape

View article
Scrip

Pfizer Well Placed To Lead First Line Advanced RCC Market

By Kevin Grogan 31 Oct 2018

Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.

Topic Cancer

View article
Pink Sheet

Alkermes Depression Drug Faces Tough Questions At US FDA Advisory Committee

By Michael Cipriano 31 Oct 2018

If approved, ALKS 5461 would be first opioid-containing product to carry indication for depression; Alkermes CEO Pops tells Pink Sheet that agency's safety and efficacy concerns are surmountable because "all depression drugs have mixed results."

View article
Scrip

On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019

By Jessica Merrill 31 Oct 2018

Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.

Topic Business strategies

View article
Scrip

Scrip Awards By Numbers 2018 Video

29 Oct 2018

Just how important is it to attend SCRIP Awards 2018? We’ve put together this short video to give you the facts and figures from last year’s awards – can you afford to miss this once-a-year opportunity?

Topic Clinical trials

Full video
Scrip

A timeline of the Takeda/Shire merger

By Mike Ward 26 Oct 2018

A staple of consumer magazines and tabloid newspapers involves coverage of celebrity relationships – who has been seen together? Who is dating? Will they become a permanent item? And are they going to live happily ever after? Readers can’t seem to get enough of it. Interestingly, while maybe not so racy as the celebrity goings-on, pharma industry watchers are keen to follow company couplings. Talk of mergers and acquisitions, one of the ways that companies can build scale, always attracts attention.

Topic Business strategies Company analysis

View interactive data
Scrip

Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads

By Ian Haydock 26 Oct 2018

As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.

Topic Parkinsons disease

View article
Scrip

Stellar Survival Data For AZ's Lynparza Hailed At ESMO

26 Oct 2018

Clinicians and analysts have lauded spectacular results presented at ESMO from the SOLO-1 trial which strongly suggest that AstraZeneca's Lynparza should be the first-line maintenance treatment of choice for ovarian cancer patients with a BRCA mutation.

Topic Drug approval Cancer

View article
Pink Sheet

Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHH's Azar Argues

By Derrick Gingery 26 Oct 2018

President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.

Topic Drug review Drug development landscape

View article
Datamonitor Healthcare

Depression Disease Market and Forecast Analysis 2024

24 Oct 2018

Informa Pharma Intelligence is marking Depression Awareness Month with a free download of Depression Disease Market and Forecast Analysis 2024. Download your free extract from this vital report and tap into the exclusive data and insights into the depression market available only from the experts at Datamonitor Healthcare, part of the Informa Pharma Intelligence suite of tools.

Topic Drug development landscape

Single report
Datamonitor Healthcare

Better Heart Health Whitepaper

22 Oct 2018

In recognition of World Heart Day, September 29, 2018, Informa Pharma Intelligence would like to invite you to download our latest whitepaper, Better Heart Health with Mobile Apps? The Impact of Mobile Apps on Coronary Heart Disease in the US. This exploration into the results of a recent analysis of the US Behavioral Risk Factor Surveillance System (BRFSS), coupled with an analysis of several health apps targeting coronary heart disease (CHD) and other heart disease factors, is available to you now – for free.

View white paper
Pink Sheet

DTC Advertising: The 'Kick Me' Sign On Big Pharma's Backs

By Michael McCaughan 18 Oct 2018

Treating mandatory wholesale acquisition cost disclosure in TV ads as a major drug pricing reform is close to ludicrous. But the broad approval of the action is an important sign of the continued public image cost of the ads to the drug companies.

Topic Drug approval Drug review

View article
Pink Sheet

Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars

By Ian Schofield 18 Oct 2018

Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.

Topic Business strategies Company analysis

View article
Scrip

Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?

By Jessica Merrill 18 Oct 2018

PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads.

Topic Drug approval Drug review

View article
Scrip

Not To Be Sniffed At: Dupixent Success In Rhinosinusitis Could Open Up Large Additional Market

By Alexandra Shimmings 18 Oct 2018

On the brink of an expanded US approval for asthma, Sanofi/Regeneron’s interleukin-4 receptor blocker Dupixent has produced positive topline Phase III data in a lucrative third indication, rhinosinusitis with nasal polyps.

Topic Influenza virus

View article

Latest headlines

Pink Sheet

14 Nov 2018

No Quick End To Brexit Activity Hold At EMA

Link
Scrip

14 Nov 2018

Alnylam Offering Value-Based Deals In EU For Breakthrough RNAi Drug Onpattro

Link
Scrip

14 Nov 2018

Mersana Back On Track After Speedy Changes To ADC Program

Link
Pink Sheet

14 Nov 2018

Bayer Consumer Health Yet To Turn Corner Due To Supply, Innovation Detours

Link
Scrip

14 Nov 2018

Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

Link
Scrip

13 Nov 2018

Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic

Link
Pink Sheet

13 Nov 2018

Scottish HTA Okays Neuroblastoma Ultra Orphan Qarziba

Link
Scrip

13 Nov 2018

Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion

Link
Pink Sheet

13 Nov 2018

Merck's View On The Challenges Of Ebola Vaccination In The DRC

Link
Scrip

13 Nov 2018

Bayer Eyes More Link-Ups Like Loxo After Pipeline Blips

Link
Pink Sheet

13 Nov 2018

Novartis And Stemline Try For Fast-Track EU Review

Link
Scrip

13 Nov 2018

INFOGRAPHIC: INFOGRAPHIC: Sweden's Vibrant And Growing Life Sciences Landscape

Link
Pink Sheet

13 Nov 2018

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

Link
Pink Sheet

13 Nov 2018

US FDA Allows Waiver Of Informed Consent For Clinical Investigations With Minimal Risk

Link
Scrip

13 Nov 2018

AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Pharmaceutical intelligence for consultancies

Your trusted pharma partner

Our unique strengths

Understand your clients’ world

Stay on top of the details

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product List

Thought leadership

Awareness

Lead generation

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store